Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 842 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Placebo Clear all
Completed Phase 2 Interventional Results available

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

NCT00955487
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide (iNO), Nitrogen (placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00332215
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Sodium Pyruvate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 30, 2008 · Synced Sep 3, 2026, 11:36 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

NCT04089852
View directory record Official record
Conditions
Contraceptive Devices, Long-Acting Reversible Contraception, Analgesia, Adolescent Health, Gynecology
Interventions
Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 24 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 3, 2026, 11:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Adenosine 2A Receptor Antagonism and AIH in ALS

NCT05377424
View directory record Official record
Conditions
ALS
Interventions
Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug, SHAM counterpart to low oxygen therapy.
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

NCT02351180
View directory record Official record
Conditions
Lung Transplant Infection
Interventions
Inhaled beclomethasone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

NCT01545440
View directory record Official record
Conditions
Asthma
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
70
States / cities
Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
PF- 00610355, Placebo, Salmeterol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Withdrawn Early Phase 1 Interventional

S-Nitrosylation Therapy of COVID-19

NCT04528771
View directory record Official record
Conditions
SARS-CoV2 Infection, Covid19
Interventions
SNO, Nitrogen gas
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Results available

Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea

NCT01196117
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
14 days of placebo therapy, 14 days of CPAP therapy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595
View directory record Official record
Conditions
Asthma
Interventions
QBX258, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Not applicable Interventional

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine Pulmonary Safety in Patients With COPD

NCT00889837
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled Loxapine, Inhaled Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
40 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional

Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants

NCT00152542
View directory record Official record
Conditions
Prematurity, Respiratory Distress Syndrome,Hypoxemia
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 6 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Project 4A: Inspiratory Muscle Training and Diaphragm Strength

NCT02367170
View directory record Official record
Conditions
Sepsis
Interventions
Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure, Midazolam, Volitional Measurement of Maximal Inspiratory Pressure (MIP), Inspiratory Muscle Strength Training (IMST), SHAM Inspiratory Muscle Strength Training (IMST), Diaphragm thickness measurement, Blood and Urine samples
Procedure · Drug · Device + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

NCT07709494
View directory record Official record
Conditions
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions
Rev-56 for Inhalation, Placebo: Normal saline
Combination Product · Drug
Lead sponsor
Revagenix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Phase 2 Interventional Results available

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

NCT02178566
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 3, 2026, 11:36 AM EDT